RussellEWareMDPhD

Pediatric Hematology & Oncology • Cincinnati, OH

Director, Division of Hematology Marjory J. Johnson Chair of Hematology Translational Research, Division of Hematology Co-Executive Director, Cancer and Blood Diseases Institute Associate Director

Join to view full profile

Dr. Ware is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ware's full profile

Already have an account?

Office
3333 Burnet Ave
# ML7015
Cincinnati, OH 45229
Phone+1 513-636-4266

Fax+1 513-636-3549

Education & Training

Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1986 - 1989
Baylor College of Medicine (Houston)Residency, Pediatrics, 1983 - 1986
Duke University School of MedicineClass of 1983

Certifications & Licensure

OH State Medical License 2013 - 2025
TN State Medical License 2004 - 2025
TX State Medical License 2012 - 2014
NC State Medical License 1987 - 2005
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Stroke With Transfusions Changing to Hydroxyurea Start of enrollment: 2006 Oct 01
Terminated
Phase 3
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea Start of enrollment: 2011 Aug 01
Terminated
Phase 3
Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) Start of enrollment: 2012 May 01
Terminated
Phase 3
EXTEND EXpanding Treatment for Existing Neurological Disease Start of enrollment: 2014 Aug 01
Active, not recruiting
Phase 2
SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia Start of enrollment: 2016 Mar 16
Active, not recruiting
Not Applicable
Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS) Start of enrollment: 2017 Mar 20
Completed
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation Start of enrollment: 2019 Dec 22
Recruiting
Repeated Employee Testing for Understanding Our Recovery to Normal Start of enrollment: 2020 May 11
Active, not recruiting
Serology to COVID-19 for Recording Exposures and Evaluating Needs Start of enrollment: 2020 Aug 18
Terminated
Alternative Dosing And Prevention of Transfusions (ADAPT) Start of enrollment: 2022 Jun 16
Recruiting
Early Phase 1
Roles: Contact, Study Director
Realizing Effectiveness Across Continents With Hydroxyurea Start of enrollment: 2023 Oct 27
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Globalization in clinical drug development for sickle cell disease.
Enrico Costa, Russell E Ware, Léon Tshilolo, Julie Makani, Hubert G M Leufkens
American Journal of Hematology. 2025-01-01
The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?
Charles T Quinn, Russell E Ware
Pediatric Blood & Cancer. 2024-12-10
Hydroxyurea for Children and Adults with Hemoglobin SC Disease.
Yvonne A Dei-Adomakoh, Catherine I Segbefia, Teresa S Latham, Adam C Lane, Klenam Dzefi-Tettey
NEJM Evidence. 2024-12-08

Abstracts/Posters

Ndepth: A Randomized Controlled Trial of a Novel Dose-Prediction Equation to Determine Maximum Tolerated Dose for Hydroxyurea Therapy in Pediatric Patients with Sickle...
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Optimizing Hydroxyurea Dosing in Sickle Cell Anemia: The Uganda MTD Study
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hydroxyurea Therapy to Prevent Incident Stroke Among Children with Sickle Cell Anaemia in Jamaica: The Extend Trial
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Stroke Avoidance for Children in RepÏblica Dominicana (SACRED):a Prospective Trial to Reduce Stroke in Children with Sickle Cell Anemia
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoiet...
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genetic Analysis in the Tanzania Sickle Surveillance Study (TS3): Modifiers of Sickle Cell Disease and Identification of Hemoglobin Variants
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Splenomegaly in Children with Sickle Cell Anemia Receiving Hydroxyurea in Sub-Saharan Africa
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Diseas...
Russell E. Ware, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Old and New Treatments for Sickle Cell Anemia: Is There a Standard of Care?
60th American Society of Hematology Annual Meeting - 11/30/2018

Other

Autoimmune hemolytic anemia in children
Ware RE
http://www.uptodate.com/contents/autoimmune-hemolytic-anemia-in-children
UpToDate, Wolters Kluwer Health - 2012-10-03

Press Mentions

NIH Funds New Project to Improve SCD Care for Children in MalawiNovember 10th, 2020
These Companies Are Seeking a Cure for Sickle Cell. And It’s Just the Beginning for Some Gene Therapy StocksJuly 24th, 2020
Higher Hydroxyurea Dose Does NOHARM in Sub-Saharan African Children with Sickle Cell DiseaseJuly 22nd, 2020
Join now to see all

Grant Support

TCD With Transfusions Changing To HydroxyureaNational Heart, Lung, And Blood Institute2011
Sparing Conversion To Abnormal TCD ElevationNational Heart, Lung, And Blood Institute2011
Hydroxyurea Pharmacokinetics And PharmacogenomicsNational Heart, Lung, And Blood Institute2011
Sickle Cell Scholar ComponentNational Heart, Lung, And Blood Institute2008–2011
Administrative CoreNational Heart, Lung, And Blood Institute2008–2011
Sparing Conversion To Abnormal TCD ElevationNational Heart, Lung, And Blood Institute2010
TCD With Transfusions Changing To HydroxyureaNational Heart, Lung, And Blood Institute2009–2010
Hydroxyurea Pharmacokinetics And PharmacogenomicsNational Heart, Lung, And Blood Institute2008–2010
Stroke With Transfusions Changing To HydroxyureaNational Heart, Lung, And Blood Institute2005–2010
Comprehensive Sickle Cell Center Composite:Basic &Translational Research ProgramNational Heart, Lung, And Blood Institute2009
Comprehensive Sickle Cell Center CompositeNational Heart, Lung, And Blood Institute2008
Core--Clinical CoreNational Heart, Lung, And Blood Institute2007
Genetic Modifiers In Children With Sickle Cell AnemiaNational Heart, Lung, And Blood Institute2004–2005
Genetic Modifiers In Children With Sickle Cell AnemiaNational Heart, Lung, And Blood Institute2001–2003
Abnormal PIG A Expression In GPI Deficient Blood CellsNational Heart, Lung, And Blood Institute1995–1999
Biology Of The Bone Marrow Derived 3A1 Stem CellNational Heart, Lung, And Blood Institute1987–1991